ADCAN Pharma Signs Five International Partnerships to Expand UAE Drug Manufacturing
UAE-based pharmaceutical manufacturer ADCAN Pharma has signed five licensing and local manufacturing agreements and binding term sheets with international partners to expand its product portfolio and strengthen medicine production across the UAE, Saudi Arabia and the wider Middle East.
The agreements were signed during CPHI Milan 2026, a global pharmaceutical industry event held in Milan from October 6 to 8. The partnerships cover medicines for cardiovascular diseases, diabetes and oncology, with a focus on licensing, technology transfer and local manufacturing.
ADCAN Pharma said the agreements form part of its strategy to increase regional production capabilities and improve access to essential medicines.
Partnerships Cover Europe and Asia
The five partners are Elpen, Alvion and Genepharm of Greece, Inventia of India, and Lotus of Taiwan.
The agreements are intended to support the transfer of pharmaceutical technologies, establish local manufacturing collaborations and expand the company’s portfolio across key therapeutic areas.
ADCAN Pharma said the partnerships would help bring critical medicines closer to patients while strengthening manufacturing capacity in the UAE, Saudi Arabia and other Middle Eastern markets.
EDE Highlights Role of Technology Transfer
Dr Shaikha Al Mazrouei, Research and Studies Advisor at the Emirates Drug Establishment (EDE), said international licensing and manufacturing partnerships were important to the development of the UAE’s pharmaceutical industry.
She said the regulator was committed to maintaining a framework that supports quality, compliance, innovation and knowledge transfer while improving the competitiveness of medicines manufactured in the UAE.
Such collaborations can help local manufacturers develop technical capabilities and support the broader objective of strengthening regional pharmaceutical production.
ADCAN Pharma Focuses on Local Production
Hamdan Mohamed AlDahmani, Chairman of ADCAN Pharma, said the agreements reflected the company’s focus on long-term partnerships to strengthen local manufacturing and expand access to essential medicines.
“Our priority is to support patient access, capability transfer, and the continued growth of the UAE and the region’s pharmaceutical sector,” AlDahmani said.
Dr Fokion Sinis, Chief Executive Officer of ADCAN Pharma, said the memoranda of understanding formed part of the company’s wider localisation strategy.
Through licensing and technology transfer, the company aims to bring critical therapies closer to patients in the UAE while developing its capabilities across cardiovascular care, diabetes and oncology in Saudi Arabia and the wider Middle East.
UAE Seeks to Strengthen Pharmaceutical Supply Chains
ADCAN Pharma said the partnerships align with the UAE’s broader healthcare and industrial priorities, including expanding domestic pharmaceutical manufacturing and strengthening medicine supply-chain resilience.
Initiatives supporting local production, including the Made in the UAE agenda, are intended to build domestic capabilities, improve access to treatment and reinforce the country’s role as a regional centre for pharmaceutical manufacturing and innovation.
The five agreements mark a further step in ADCAN Pharma’s efforts to build international partnerships and expand its presence across the region’s pharmaceutical market.
